Neurocrine Biosciences Inc (NBIX) Financials

Key financial figures for Neurocrine Biosciences Inc (Q3 2026).

Neurocrine Biosciences, Inc. reported revenue of $1.12 billion for Q3 FY2026, up 41.2% from the same period a year earlier. Net income was $206.5 million, or $1.96 per share. Operating margin came to 29.51%, against 30.07% a year earlier. Free cash flow for the period was $383.6 million. Across the last 5 reported quarters, quarterly revenue has risen from $794.9 million in Q3 FY2025 to $1.12 billion in Q3 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Neurocrine Biosciences, Inc. are on the SentiSense financials page.

Revenue
$1.1B
Net Income
$207M
EPS
$2.03
Total Assets
$5.6B
Operating Cash Flow
$395M

Recent quarters

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
Q3 FY2026$1.1B$207M$1.9629.51%$384M
Q2 FY2026$959M$144M$1.3915.95%$129M
Q1 FY2026$815M$198M$1.9122.84%$137M
Q4 FY2025$806M$154M$1.4826.18%
Q3 FY2025$795M$210M$2.0430.07%$214M

Recent fiscal years

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
FY2025$2.9B$479M$4.6721.64%$749M
FY2024$2.4B$341M$3.2924.22%$557M
FY2023$1.9B$250M$2.4713.3%$362M

Frequently asked questions

What was Neurocrine Biosciences, Inc.'s revenue last quarter?

Neurocrine Biosciences, Inc. reported revenue of $1.12 billion for Q3 FY2026, up 41.2% from the same period a year earlier.

Is Neurocrine Biosciences, Inc. profitable?

Yes. Neurocrine Biosciences, Inc. reported net income of $206.5 million for Q3 FY2026, a net margin of 18.39% on revenue.

How has Neurocrine Biosciences, Inc.'s margin trended?

Operating margin was 29.51% in Q3 FY2026, compared with 30.07% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.

How much free cash flow did Neurocrine Biosciences, Inc. generate?

Neurocrine Biosciences, Inc. generated free cash flow of $383.6 million in Q3 FY2026, after capital expenditure.

Full income statement, balance sheet and cash flow for Neurocrine Biosciences Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.